Literature DB >> 23402797

Contrast-enhanced magnetic resonance angiography in diabetic patients with infra-genicular peripheral arterial disease: systematic review.

D A Healy1, E M Boyle, M Clarke Moloney, P A Hodnett, T Scanlon, P A Grace, S R Walsh.   

Abstract

OBJECTIVE: Diabetes is a leading risk factor for the development of peripheral arterial disease (PAD). The optimal imaging modality for patients with diabetes and PAD is uncertain. We sought to analyse the literature to determine the accuracy of contrast enhanced magnetic resonance angiography (CE-MRA) in differentiating extent of disease in patients with infragenicular PAD and diabetes, using digital subtraction angiography (DSA) as the gold standard.
METHODS: Online databases were searched for relevant keywords (January 1998-June 2012). Eligible studies prospectively compared CE-MRA and DSA of infragenicular vessels and provided data to construct contingency tables in at least 10 patients with diabetes and PAD symptoms. Pooled sensitivity and specificity values were calculated using random effects modelling.
RESULTS: Only three studies (83 patients) provided data regarding the infragenicular vessels. The pooled sensitivity of MRA was 86% while the pooled specificity of MRA was 93%.
CONCLUSIONS: The assumptions regarding CE-MRA's efficacy for infragenicular disease in diabetics are based upon low patient numbers. Inadequate diagnostic imaging in this high-risk group risks adoption of incorrect revascularisation strategies. Further studies are required.
Copyright © 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23402797     DOI: 10.1016/j.ijsu.2013.02.001

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  2 in total

Review 1.  Noninvasive Arterial Testing: What and When to Use.

Authors:  Derek Mittleider
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

Review 2.  Vascular imaging in diabetes.

Authors:  K Levitt; L Vivas; B Courtney; K A Connelly
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.